Amylyx Pharmaceuticals, Inc. 4

Gina Mazzariello, Chief Legal Officer of Amylyx Pharmaceuticals, Inc. (AMLX), automatically sold 9,536 shares of common stock on September 10, 2026 to cover tax withholding from vested performance stock units, retaining 190,838 shares afterward.

On September 10, 2026, Gina Mazzariello, Chief Legal Officer of Amylyx Pharmaceuticals, Inc., sold an aggregate 9,536 shares of Amylyx common stock in two Form 4-reported transactions at weighted average prices of approximately $32.46 and $33.34 per share, respectively, for total proceeds of roughly $309,000. According to the filing, these sales were effected automatically and solely to satisfy tax withholding obligations arising from the vesting of performance stock units, and thus were not discretionary open‑market sales. Following these transactions, Mazzariello beneficially owned 190,838 shares of Amylyx common stock. Given the routine, tax‑related nature of the sales and their modest size relative to typical insider activity thresholds, this filing suggests administrative portfolio adjustments rather than a change in fundamental insider sentiment.

Filing Facts

CIK

1658551

Ticker

AMLX

Form

4

Source Type

fda

Accession

0001193125-26-390508

Alert Tier

5